Abstract
The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We show that in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility and histone modification level that can be partially recapitulated in an orthogonal cell line system by the introduction of H3.3-G34W. These epigenetic alterations affect mainly heterochromatic and bivalent regions and provide possible explanations for the genomic instability as well as the osteolytic phenotype of GCTB. The mutation occurs in differentiating mesenchymal stem cells and associates with an impaired osteogenic differentiation. We propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3 WT and H3.3 MUT stromal cells and add to H3.3-G34W associated changes.
Important abbreviations H3.3-G34W, mutated histone variant; H3.3 MUT, stromal cells expressing H3.3-G34W; H3.3 WT, stromal cells expressing wildtype H3.3
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was in part supported by Funds from the Helmholtz Foundation (C.P.), the Korean National Cancer Center (Grant No. 1810050-1 to A.M.L.), the Korean National Research Fund (Grant No. 2017R1E1A1A01073670 to A.M.L.), Oxford NIHR BRC (U.O.), Arthritis Research UK (program grant 20522 to U.O.). P.L., A.B. are DKFZ Postdoctoral Fellows. P.L. was supported by the Hemlholtz Association AMPro Project (ZT00026). A.K., A.M.T., D.M. are fellows of the Helmholtz International Graduate School for Cancer Research, J.H. is fellow of the German-Israeli Helmholtz Graduate School, C.J. is a recipient of a PhD fellowship from the Royal Commission for the Exhibition 1851, China-Oxford Scholarship Fund and UCB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics comittee Heidedelberg
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All raw sequencing data from WGS, WGBS, ATAC-seq, ChIP-seq, RNA-seq and deep targeted resequencing were obtained from patient samples (therefore restricted) and are being uploaded to European Genome-Phenome Archive (EGA): EGA: EGAS00001003730. Processed sequencing data and microarray data are being uploaded to the ArrayExpress database (E-MTAB-7184). All presented results were obtained with the use of published and publicly available software tools introduced in the Methods section.
